Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
de Bruin-Weller, Marjolein (University Medical Center Utrecht)
Serra-Baldrich, E (Institut d'Investigació Biomèdica Sant Pau)
Barbarot, Sebastien (Department of Dermatology. Nantes Université. CHU Nantes. INRAE)
Grond, Susanne (Eli Lilly and Company)
Schuster, Christopher (Eli Lilly and Company)
Petto, Helmut (Eli Lilly and Company)
Capron, Jean-Philippe (Eli Lilly and Company)
Raibouaa, Afaf (Eli Lilly and Company)
Werfel, Thomas (Division of Immunodermatology and Allergy Research. Department of Dermatology and Allergy. Hannover Medical School)
Universitat Autònoma de Barcelona

Data:	2022
Resum:	Introduction: Indirect treatment comparison was used to compare approved doses of baricitinib and dupilumab for treating adult patients with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy. Methods: Baricitinib and dupilumab were compared (Bucher method) at weeks 4 and 16. Performance in combination with topical corticosteroids (TCS) was analyzed in patients with inadequate response or inadvisable to topical therapies (population A) and cyclosporine (population B). Population A was additionally examined as monotherapy. Results: For the Eczema Area and Severity Index (EASI) 75, baricitinib and dupilumab were similar. A ≥ 4-point improvement in itch numerical rating scale (NRS) was significantly more likely with baricitinib 4 mg than dupilumab in population A as monotherapy (RR = 2. 62, 95% CI 1. 22, 5. 61, p = 0. 013) and in TCS combination at week 4. These differences were not significant by week 16. For the Dermatology Life Quality Index (DLQI), baricitinib 4 mg and dupilumab were similar on mean difference in change from baseline (MDcfb), though some differences were seen between baricitinib 2 mg and dupilumab at week 16 for the population A monotherapy (MDcfb = 2. 05, 95% CI 0. 53, 3. 56, p = 0. 016) and TCS combination therapy (MDcfb = 2. 48, 95% CI 0. 46, 4. 50, p = 0. 016) groups, and in population B (MDcfb = 3. 38 95% CI 1. 18, 5. 58, p = 0. 003). Conclusions: Baricitinib potentially offers more rapid improvement in itch while providing similar efficacy on EASI75 and DLQI outcomes compared with dupilumab.
Nota:	Altres ajuts: Eli Lilly and Company.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Atopic dermatitis ; Indirect treatment comparison ; Systemic therapies
Publicat a:	Dermatology and Therapy, Vol. 12 Núm. 6 (june 2022) , p. 1481-1491, ISSN 2190-9172

DOI: 10.1007/s13555-022-00734-w
PMID: 35543919

11 p, 464.0 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats